Last reviewed · How we verify
Rejuveinix Low Dose
At a glance
| Generic name | Rejuveinix Low Dose |
|---|---|
| Also known as | RJX Low |
| Sponsor | Reven Pharmaceuticals, Inc. |
| Modality | Small molecule |
| Phase | Phase 1 |
Approved indications
Common side effects
Key clinical trials
- Revascularization of Stenosed Vessels Using Optimized Treatment of Rejuveinix for Reversing Endothelial Dysfunction (PHASE1, PHASE2)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Rejuveinix Low Dose CI brief — competitive landscape report
- Rejuveinix Low Dose updates RSS · CI watch RSS
- Reven Pharmaceuticals, Inc. portfolio CI